TOXIC EPIDERMAL NECROLYSIS IN A CHILD


Cite item

Full Text

Abstract

Modern concepts on the etiology, pathogenesis, clinical manifestations, therapy, and prognosis of toxic epidermal necrolysis are presented. A clinical case in a girl aged 10 years is described; clinical course and treatment errors are discussed.

About the authors

V. I Albanova

I.M.Setchenov First Moscow Medical University

Email: albanova@rambler.ru
доктор мед. наук, профессор; Кафедра кожных и венерических болезней (зав. — проф. В.А.Молочков) ФППОВ

O. Yu Brunova

G.N.Speransky Municipal Pediatric Clinical Hospital No. 9

Email: ORITDGKB9@yandex.ru
Intensive Care Department for Infectious Patients

A. A Korsunsky

G.N.Speransky Municipal Pediatric Clinical Hospital No. 9

доктор мед. наук, профессор

References

  1. Barvaliya M., Sanmukhani J., Patel T., Paliwal N., Shah H., Tripathi C. Drug-induced Stevens—Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS-TEN overlap: a multicentric retrospective study. J. Postgrad. Med. 2011; 57(2):115—9.
  2. Lyell A. Toxic epidermal necrolysis: an eruption resembling scalding of the skin. Br. J. Dermatol. 1956; 68(11): 355—61.
  3. Stevens A.M., Johnson F.C. A new eruptive fever associated with stomatitis and ophtalmia; report of two cases in children. Am. J. Dis. Children. 1922; 24: 526—33.
  4. French LE Review Toxic epidermal necrolysis and Stevens — Johnson syndrome: our current understanding. Allergol Int. 2006; 55(1): 9—16.
  5. Norris J.M., Stuttaford L.H., Dowds L.F. Severe antiretroviral therapy-induced toxic epidermal necrolysis in a child. Case Rep. Dermatol. 2012; 4(1): 31—6.
  6. Auquier-Dunant A., Mockenhaupt M., Naldi L., Correia O., Schroder W., Roujeau J.C. Correlations between clinical patterns and causes of erythema multiforme majus, Stevens—Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study. Arch. Dermatol. 2002; 138(8): 1019—24.
  7. Tay Y.K., Huff J.C., Weston W.L. Mycoplasma pneumoniae infection is associated with Stevens—Johnson syndrome, not erythema multiforme (von Hebra). J. Am. Acad. Dermatol. 1996; 35(5, Pt 1): 757—60.
  8. Mulvey J.M., Padowitz A., Lindley-Jones M., Nickels R. Mycoplasma pneumonia associated with Stevens—Johnson syndrome. Anaesth. Intensive Care. 2007; 35(3):414—7.
  9. Leigh I.M., Mowbray J.F., Levene G.M., Sutherland S. Recurrent and continuous erythema multiforme: a clinical and immunological study. Clin. Exp. Dermatol. 1985; 10(1): 58—67.
  10. Жерносек В.Ф., Дюбкова Т.П. Синдром Стивенса—Джонсона — токсический эпидермальный некролиз у детей. Часть 1. Определение, этиология, патогенез, клинические проявления, системное лечение. Педиатрическая фармакология. 2011; 1: 30—8
  11. Зрячкин Н.И., Макарова О.А., Сигарева А.Е., Базалицкий М.М., Зайцева Г.В., Каральская Ж.Ж. Синдром Лайелла у ребенка 9 месяцев. Педиатрия. Журнал им. Г.Н. Сперанского. 2011; 6: 152—4.
  12. Mockenhaupt M. The current understanding of Stevens— Johnson syndrome and toxic epidermal necrolysis. Expert Rev. Clin. Immunol. 2011; 7(6): 803—13.
  13. Murata J., Abe R., Shimizu H. Increased soluble Fas ligand levels in patients with Stevens—Johnson syndrome and toxic epidermal necrolysis preceding skin detachment. J. Allergy Clin. Immunol. 2008; 122(5): 992—1000.
  14. Sethuraman G., Sharma V.K., Pahwa P., Khetan P. Causative drugs and clinical outcome in Stevens—Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and SJS-TEN Overlap in Children. Indian J. Dermatol. 2012; 57(3): 199—200.
  15. Жерносек В.Ф., Дюбкова Т.П. Синдром Стивенса— Джонсона — токсический эпидермальный некролиз у детей. Часть 2. Системное, местное лечение. Педиатрическая фармакология. 2011; 2: 22—6.
  16. Kardaun S.H., Jonkman M.F. Dexamethasone pulse therapy for Stevens—Johnson syndrome/toxic epidermal necrolysis. Acta Derm. Venereol. 2007; 87(2): 144—8.
  17. Schneck J., Fagot J.P., Sekula P., Sassolas B., Roujeau J.C., Mockenhaupt M. Effects of treatments on the mortality of Stevens—Johnson syndrome and toxic epidermal necrolysis: A retrospective study on patients included in the prospective EuroSCAR Study. J. Am. Acad. Dermatol. 2008; 58(1): 33—40.
  18. Del Pozzo-Magana B.R., Lazo-Langner A., Carleton B., Castro-Pastrana L.I., Rieder M.J. A systematic review of treatment of drug-induced Stevens—Johnson syndrome and toxic epidermal necrolysis in children. J. Popul. Ther. Clin. Pharmacol. 2011; 18(1): 121—33.
  19. Phan T.G., Wong R.C., Crotty K., Adelstein S. Toxic epidermal necrolysis in acquired immunodeficiency syndrome treated with intravenous gammaglobulin. Australas J. Dermatol. 1999; 40(3): 153—7.
  20. Cattelan A.M., Trevenzoli M., Sasset L., Sgarabotto D., Lanzafame M., Meneghetti F. Toxic epidermal necrolysis induced by nevirapine therapy: description of two cases and review of the literature. J. Infect. 2001; 43(4): 246—9.
  21. Claes P., Wintzen M., Allard S., Simons P., De Coninck A., Lacor P. Nevirapine-induced toxic epidermal necrolysis and toxic hepatitis treated successfully with a combination of intravenous immunoglobulins and N-acetylcysteine. Eur. J. Intern. Med. 2004; 15(4): 255—8.
  22. Trent J.T., Fangchao M., Kerdel F., Fie S., French L.E., Romanelli P., Kirsner R.S. Dose of intravenous immunoglobulin and patient survival in SJS and toxic epidermal necrolysis. Expert Rev. Dermatol. 2007; 2(3): 299—303.
  23. Valeyrie-Allanore L., Wolkenstein P., Brochard L., Ortonne N., Maitre B., Revuz J., et al. Open trial of ciclosporin treatment for Stevens—Johnson syndrome and toxic epidermal necrolysis. Br. J. Dermatol. 2010; 163(4): 847—53.
  24. Yip L.W., Thong B.Y., Lim J., Tan A.W., Wong H.B., Handa S., Heng W.J. Ocular manifestations and complications of Stevens— Johnson syndrome and toxic epidermal necrolysis: an Asian series. Allergy. 2007; 62(5): 527—31.
  25. Widgerow A.D. Toxic epidermal necrolysis - management issues and treatment options Int. J. Burns Trauma. 2011; 1(1): 42—50.
  26. Wright J.B., Lam K., Buret A., Olson M.E., Burrell R.E. Early healing events in a porcine model of contaminated wounds: effects of nanocrystalline silver on matrixmetalloproteinases, cell apoptosis, and healing. Wound Rep. Regen. 2002; 10(1): 141—5.
  27. Bhattacharya S., Tripathi H.N., Gupta V., Nigam B., Khanna A. Collagen sheet dressings for cutaneous lesions of toxic epidermal necrolysis. Indian J. Plast. Surg. 2011; 44(3): 474—7.
  28. Finkelstein Y., Soon G.S., Acuna P., George M., Pope E., Ito S., et al. Recurrence and outcomes of Stevens—Johnson syndrome and toxic epidermal necrolysis in children. Pediatrics. 2011; 128(4): 723—8.
  29. Revuz J., Penso D., Roujeau J.C., Guillaume J.C., Payne C.R., Wechsler J. Toxic epidermal necrolysis. Clinical findings and prognosis factors in 87 patients. Arch. Dermatol. 1987; 123(9): 1160—5.
  30. Hernandez-Mondragon L.O., Rio B., Partida-Gaytan A., Almeida-Gutierrez E., Rosas-Vargas M.A. 396 risk factors associated to mortality in mexican children with Stevens—Johnson Syndrome/Toxic Epidermal Necrolysis. World Allergy Organ J. 2012; 5(Suppl. 2): S143—S144.
  31. Bastuji-Garin S., Fouchard N., Bertocchi M., Roujeau J.C., Revuz J., Wolkenstein P. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J. Invest.Dermatol. 2000; 115(2): 149—53.
  32. Harr T., French L.E. Toxic epidermal necrolysis and Stevens— Johnson syndrome Orphanet. J. Rare Dis. 2010; 5(1): 39.

Copyright (c) 2013 Eco-Vector


 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies